Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy

Abstract

Arterial and pulmonary artery catheters were used to monitor the cardiopulmonary effects of recombinant interleukin-2 (rIL-2) given iv at a dose of 100, 000 U/kg every 8 hours on days 1–5 to 10 patients with metastatic solid tumors. As anticipated, a severe capillary leak syndrome developed in all patients. Myocardial infarction(MI) occurred unexpectedly in three patients, as evidenced by a focal injury pattern on ECG and elevations of creatinine phosphokinase myocardial band fractions. All patients receiving rIL-2 exhibited major reductions in their left ventricular stroke work index (47 ± 11g.m/m² to 29 ± g.m/m²), an index of cardiac contractility. It remains uncertain whether the MIs were a by product of the capillary leak syndrome in patients with underlying coronary artery disease or whether rIL-2 directly or indirectly damages cardiac muscle. [J Natl Cancer Inst 1989;81:59–63]